ALNY Alnylam Pharmaceuticals Inc

$452.00

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/6/2025

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.alnylam.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1178670
Address
675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US
Valuation
Market Cap
$30.36B
P/E Ratio
nan
PEG Ratio
-0.49
Price to Book
452.51
Performance
EPS
$-2.18
Dividend Yield
Profit Margin
-12.40%
ROE
-1501.00%
Technicals
50D MA
$251.88
200D MA
$258.96
52W High
$304.39
52W Low
$141.98
Fundamentals
Shares Outstanding
129M
Target Price
$315.43
Beta
0.30

ALNY EPS Estimates vs Actual

Estimated
Actual

ALNY News & Sentiment

Oct 01, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Sep 30, 2025 • Benzinga SOMEWHAT-BULLISH
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Sep 30, 2025 • GlobeNewswire NEUTRAL
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Sep 26, 2025 • Benzinga SOMEWHAT-BULLISH
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion.
Sep 25, 2025 • Benzinga SOMEWHAT-BULLISH
What's Going On With Intellia Therapeutics Stock Thursday - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ: NTLA ) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran ( nex-z ) for the treatment of hereditary ATTR amyloidosis with polyneuropathy ( ATTRv-PN ) .
Sep 24, 2025 • Zacks Commentary BULLISH
Why Alnylam Pharmaceuticals ( ALNY ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment Snapshot

Average Sentiment Score:

0.296
50 articles with scored sentiment

Overall Sentiment:

Bullish

ALNY Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.36 Surprise
  • Reported EPS: $-0.01
  • Estimate: $-0.37
  • Whisper:
  • Surprise %: 97.3%
Feb 13, 2025
Dec 31, 2024 (Pre market)
0.2 Surprise
  • Reported EPS: $0.06
  • Estimate: $-0.14
  • Whisper:
  • Surprise %: 142.5%
Oct 31, 2024
Sep 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $-0.87
  • Estimate: $-0.93
  • Whisper:
  • Surprise %: 6.5%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.95 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-1.08
  • Whisper:
  • Surprise %: 88.0%
May 02, 2024
Mar 31, 2024 (Pre market)
0.66 Surprise
  • Reported EPS: $-0.52
  • Estimate: $-1.18
  • Whisper:
  • Surprise %: 55.9%
Feb 15, 2024
Dec 31, 2023 (Pre market)
0.22 Surprise
  • Reported EPS: $-1.10
  • Estimate: $-1.32
  • Whisper:
  • Surprise %: 16.7%
Nov 02, 2023
Sep 30, 2023 (Pre market)
2.49 Surprise
  • Reported EPS: $1.15
  • Estimate: $-1.34
  • Whisper:
  • Surprise %: 185.8%
Aug 03, 2023
Jun 30, 2023 (Pre market)
-0.84 Surprise
  • Reported EPS: $-2.21
  • Estimate: $-1.37
  • Whisper:
  • Surprise %: -61.3%
May 04, 2023
Mar 31, 2023 (Pre market)
0.37 Surprise
  • Reported EPS: $-1.40
  • Estimate: $-1.77
  • Whisper:
  • Surprise %: 20.9%

Financials